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moderate and high risk categories as Atypical 
glandular cell (AGC), Atypical glandular cell 
favouring neoplasia (AGC-FN),  Atypical 
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significance(AG-US), Atypical squamous cell 
of undetermined significance (ASC-US),  
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ABSTRACT:
Background: Cervical cancer is a preventable and potentially curable cancer when detected early, 
yet it continues to be among the leading causes of cancer death in developing countries.   Screening 
for cervical dysplasia is critical for early detection in order to reverse this trend.  Several traditional 
screening methods such as pap smear test, HPV-DNA screening test, visual inspection with acetic 
acid or lugol iodine are in vogue with different specificity and sensitivity. LuViva advanced cervical 
scan is a new automated screening tool that has great promise for the detection of the disease in its 
earliest form both in developing and developed countries.
Objective: This study was designed to describe our experience with the use of LuViva advanced 
cervical scan as a primary screening tool for cervical dysplasia.
Method: This is a descriptive cross-sectional study, whose data was obtained from the free health 
th stscreening for civil servants in Ekiti State conducted between 11  and 21  February, 2014. Screening 
for Cervical dysplasia was conducted using the LuViva advanced cervical scan for women 40 years 
old and above.   The result was automatically recorded and transferred to an Excel sheet for 
analysis.
Result: A total sum of 254 patients was screened during the study period.  Only one patient had a 
prior pap smear done. The automated self-reporting LuViva scan presented the result of the benign 
changes on the cervix as low risk in 143 patients (56.3%), moderate risk in 52 patients (15%) and 
high risk in 59 patients (11.5%).   The machine further classified the dysplastic changes of the low, 
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Atypical squamous cell where high grade cannot be excluded (ASC-H) and Low grade squamous 
Intraepithelial lesion (LSIL).  The proportion of moderate and high risk AGC (31.2%) was just 
slightly lower than the moderate and high risk of ASC-US (35.2%) while a higher percentage 
of43.9% in low grade squamous intraepithelial lesion was recorded among the patients. 
Conclusion:  Our experience suggests that there is a place for the use of luViva scan in the primary 
screening for cervical dysplasia and there is a correlation between LuViva scan high risk result and 
histological diagnosis of cervical dysplasia.
INTRODUCTION
4-7
because of sampling errors. New technologies 
continue to emerge in a bid to ensure effective 
screening for cervical dysplasia, one of these is 
4,7,8
the LuViva advanced cervical scan.
LuViva is designed as a fast, painless, non-
invasive test that has the potential to significantly 
improve the early detection of cervical 
4,7,8
dysplasia.    It identifies and quickly analyze 
light reflected from the cervix using a 
combination of fluorescence and reflectance 
spectroscopy to scan the cervix distinguishing 
between normal and diseased tissue by detecting 
biochemical and morphological changes at the 
4,7,8
cellular level.
The LuViva Scan is a point-of-care device that 
can detect cervical disease up to two years earlier 
than Pap test, HPV test, colposcopy and biopsy, 
eliminating the high number of unnecessary, 
painful and costly testing of conventional tissue 
4,7,8
sample methods.    It is therefore a cost 
effective screening method.   A study using 
LuViva machine reduced the number of 
4
unnecessary biopsy by about 40%. The test is 
4
effective on women of all ages.
The LuViva scan identified 100% of all cervical 
disease cases in a blinded clinical study, also 
correctly identified 44% of women who had a 
previous abnormal Pap test and who were 
determined to be false positives as part of the 
8
study. The machine is positioned to address the 
Cervical cancer is a curable disease when 
detected early as it usually begins slowly with 
recognizable dysplastic changes which 
progresses gradually over 10-20 years, yet it 
remains the commonest genital tract malignancy 
1
worldwide.   Globally there are 471,000 cases of 
cervical cancer diagnosis annually and about 
233,000 deaths yearly, of which 85% of these 
deaths occur in low and middle-income 
2-4
countries.    It is the second most common 
female cancer and the second leading cause of 
5-6
cancer death in women globally.    Most 
women with dysplasia have no symptom,  
therefore screening tests are very important.
There are many modalities of screening for 
dysplasia which significantly reduce the disease 
burden.  These include Pap smear test which 
could be the traditional Cytology, Automated 
2-3
Cytology or Liquid base Cytology.    Human 
papilloma virus (HPV-DNA) testing, Visual 
inspection with acetic acid (VIA), Visual 
inspection with acetic acid and magnification 
(VIAM), Visual inspection with lugol iodine 
(VILI) and Cervicography are also other 
2,3
modalities of screening.
However the Pap test, which is the gold standard 
is not a perfectly reliable measure because 
between 15% to 25% of Pap smear test are false-
negative results and as many as 25% of invasive 
cervical cancer cases escape early detection 
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tremendous unmet need in developed  countries 
to reduce the high number of false positive 
results created by conventional testing but even 
present greater opportunity in the developing 
world to detect disease where the infrastructure 
to support conventional laboratory-based 
4,7,8,9testing may be lacking or inadequate.
A study conducted on 55 women who had 
positive Pap tests concluded that there is high 
sensitivity, specificity and high negative 
10predictive value of LuViva. The scan offers the 
potential of a cost effective test that provides an 
immediate result while detecting significantly 
more of moderate and high grade dysplasia and 
significantly reducing the need for additional 
4,7,9testing for  benign and CIN I lesions.    Test 
results are immediately reported as one of three 
levels; low, moderate or high which helps the 
physician decide whether a colposcopy 
9examination and biopsy is indicated. LuViva 
effectively triages women at risk for cervical 
cancer, especially those with ASC-US or LSIL 
10Paps or with evidence of high risk HPV.
The LuViva scan detects cervical dysplasia with 
sensitivity of greater than 90% compared with 
76% sensitivity for the current standard of care 
methods and can be used effectively in primary 
screening considering the limitation of routine 
4pap test. This study presents our experience with 
the use of LuViva advanced cervical scan as a 
primary screening tool for cervical dysplasia.
MATERIALS AND METHODS
This is a descriptive cross-sectional study,whose 
data was obtained from the free health screening 
for civil servants at the Ekiti State Government 
th stsecretariat between 11  and 21  of February, 
2014.   The intervention included screening for 
metabolic diseases such as hypertension, and 
diabetes mellitus and cancers of the prostate, 
colon, breast and the cervix. Screening for 
cervical dysplasia, which is the precursor of 
cervical cancer was conducted using the LuViva 
advanced cervical scan (Guided Therapeutics 
Inc. GA, USA. 2012).   The screening was done 
in a designated examination room in the data 
bank of the state ministry of health.
The study population consisted of female civil 
servants from the various ministries who were 
40 years and above, who were not menstruating 
at the time of the screening and who consented 
for the test.   Age limits was imposed because of 
limited resources.   Eligible patients were 
referred from the various screening points for 
cervical screening.   The procedure was 
explained to the patients on arrival, basic 
information was obtained and they were 
prepared for the procedure.
The scan was conducted by a team that consisted 
of a consultant Gynaecologist, consultant family 
physician, a resident in Obstetrics and 
Gynaecology, and medical officers from the 
state ministry of health.   The team was trained 
on the use of the LuViva scan prior to the 
screening.   The patients involved in the training 
were not included in the final analysis.  
Confidentiality and privacy was ensured in the 
screening room and the result was discussed 
with each patient before she exits the room.   
The scan was used as a primary screening tool.  
Almost all the patients had not had any cervical 
screening prior to the exercise.   This was 
indicated as 'test result not available' option on 
the relevant cytology input dialog on the 
machine.
The LuViva scan produced results for each 
patient based on 8 distinct categories as follows; 
Negative, Benign changes, Atypical glandular 
cell (AGC), AGC-favour neoplasm, AGC-
undetermined significance (AGC-US), Atypical 
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squamous cell-where high grade could not be 
excluded (ASH-H) Atypical squamous cell of 
undetermined significance ASC-US) and Low 
grade squamous intraepithelial lesion (LSIL).   
The only exception was the patient who had a 
previous Pap smear result that was inputted into 
the LuViva scan.   She had a solitary result 
output.   The risk for dysplasia was assessed as 
low, moderate or high risk.   Patients adjudged 
as high risk for dysplasia were referred to the 
State Specialist Hospital, Ikere Ekiti for 
colposcopy and biopsy.   Moderate and low risk 
patients were given appointments ranging from 
6-12 months and 3 years respectively for follow 
up screening.
The result that was automatically generated by 
the scan was printed out.  The printed result was 
transferred to an Excel sheet in which the result 
was stored and analyzed.   The data is presented 
in frequency tables, percentages and charts.   
The output was assessed to reveal our 
experience with the LuViva scan as primary 
screening tool for cervical dysplasia.
Ethical approval for the study was obtained 
from the state ministry of health ethical 
committee.
RESULTS
A total of 254 patients were screened during the 
study period.   Eligible age was limited to 40 
years and above due to limited resources.   Four 
patients below the age of 40 years however got 
involved in the screening.   This is shown in 
Table 1.   Only one patient had prior Pap smear 
done before the exercise (Table 2).
The LuViva scan presented result as low, 
moderate or high risk for all the various 
categories of the cytological classification in all 
the patients except the patient with a prior Pap 
smear result that had a single result presented 
under the Negative for dysplasia column.   The 
result for this patient with Pap smear result which 
was Negative for intraepithelial lesion or 
malignancy was described as low risk on LuViva 
scanning.
Analysis of the result showed low, moderate or 
high risk for Negative finding for dysplasia, as 
shown in Table 3A, with 17 patients (6.7%) 
having high risk.   Also, the result for Benign 
changes were presented as low, moderate or high 
risk, with 29 patients (11.5%) having high risk 
(Table 3B).   The same pattern was observed in 
all the other 6 categories as shown in Table 3C.
The result of each patient was summarized using 
highest risk on screening for the various 
parameters.   Low risk was adjudged in 143 
patients (56.3%), moderate risk in 52 patients 
(20.5%) and high risk in 59 patients (23.2%). 
This was further sub classified using the age 
distribution and presented in Figure 1.
High risk for atypical glandular cells was 
observed in 40 patients (15.8%) and atypical 
glandular cells of undetermined significance 
were observed in 42 patients (16.6%).   All the 
patients with high risk for AGC-favouring 
neoplasm were also stated as high risk of AG-
undetermined significance(Figure 2).
Forty five patients (17.8%) were shown to have 
high risk for atypical squamous cell of 
undetermined significance (ASC-US).   These 
patients were observed to be a subset of the total 
number of 53 patients (20.9) with high risk for 
atypical squamous cell – where high grade could 
not be excluded (ASC-H), who were also a 
subset of the total number of 59 patients (23.3%) 
with high risk for low grade squamous 
intraepithelial lesion.   This was presented in 
Figure 3.
 Preliminary report on the result of histology of 
colposcopy directed biopsy of the patients 
86
Trop J Obstet Gynaecol, 31 (2), August 2014
adjudged as high risk (only nineteen presently 
available) showed 2 patients with CIN1, 8 
patients with CIN II and 9 patients with CIN III 
(a patient with Carcinoma Insitu).    Other 
histology results are being awaited and the 
follow up appointments for other patients would 
create sufficient data for analysis.
DISCUSSION
This study describes our experience with the use 
of LuViva advanced cervical scan as a primary 
tool in cervical screening for predicting the risk 
of cervical dysplasia.  No previous 
documentation of the use of the scan as a 
primary tool has been done in Nigeria or in the 
West African subcontinent.  Previous studies 
using the Luviva scan machine were conducted 
on patients with abnormal pap smear.  A 
multicenter pivoted study involving 1607 
patients showed a sensitivity of 91% in the 
detection of CINII+ compared to 76% for 
12
standard of care with pap smear .  Bentley et al 
(2014) also observed a sensitivity of 100% in the 
detection of high grade dysplasia in patients 
referred on account of abnormal pap smear 
result.
The result of this study showed low risk in 143 
patients (56.3%), moderate risk in 52 patients 
(20.5%) and high risk in 59 patients (23.2%).  
This is at variance with the findings of Bentley et 
al (2014) where 23.6%, 12.7% and 63% were 
observed for low, moderate and high risk 
respectively.  This is understandable because the 
55 patients in their study were referred on 
account of abnormal pap smear result compared 
to a primary screening tool undertaken in this 
10
study. In their study, all the patients with high 
grade cervical dysplasia were correctly 
identified as high grade risk on Luviva scan.  In 
this study, all the patients classified as high risk 
(59 patients) were sent for histological diagnosis 
and nineteen (19) of them came back with results 
while the rest of them are yet to present for 
followup.  This however further highlight  the 
low level of health seeking behavior of people in 
this locality considering the population involved 
with their level of literacy and the opportunity 
that early detection of cervical dysplasia offers 
in the prevention and treatment of cervical 
cancer.  This is further reflected in the fact that 
only a patient (0.39%) among female civil 
servants who presented for the exercise has had a 
documented pap smear before the screening 
exercise.  The nineteen histology results 
available so far for moderate to high risk patients 
in the study showed 2 patients with CIN I, 8 
patients with CIN II and 9 patients with CIN III.  
Among the patients with histology report, the 
ability of the machine to recognize CIN II and 
CIN III is about 89%.  Though the sample size is 
small, the result is consistent with those of 
Bentley et al 2014 whose patients had previous 
abnormal results.  The LuViva scan result for 
various cytological classification showed a 
distribution for negative for dysplasia in the 
range of low, moderate to high risk, with 17 
patients (6.7%) showing high risk.  The same is 
applicable to the results for benign changes 
which also had 29 patients (11.4%) showing 
high risk for dysplasia.  The analysis showed 
high risk for atypical glandular cells occurring in 
40 patients (15.8%).  There was no 
discrimination between high risk for atypical 
cells which favours neoplasm [41 patients 
(16.2%)] and high risk for atypical glandular 
cells with undetermined significance [42 
patients (16.6%)].  There was also no 
discrimination between atypical squamous cell, 
where high grade could not be excluded (ASC-
H) and low grade squamous intra epithelial 
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lesion 53(20.9%) and 59 (23.3%) respectively.  
The pattern showed the patients with high risk 
for ASC-H observed to be subset of patients 
with high risk for LSIL.  There was also a 
similar distribution for the low and moderate 
risk between the two categories (148(58.5%), 
52(20.6%) and 142(56.1%), 52(20.6%) 
respectively).  The results were therefore 
adjudged not to be specific on the cytological 
classification demonstrated.
The automated classification of the dysplastic 
changes of the low, moderate and high risk 
categories as AGC, AGC-FN, AG-US, ASC-
US, ASC-H and LSIL may be useful for follow 
up when used as primary screening and also to 
study the dynamics of the disease.  The 
proportion of moderate and high risk AGC 
(31.2%) is just slightly lower than the moderate 
and high risk of ASC-US(35.2%) while a higher 
percentage  of  low grade  squamous  
intraepithelial lesion of 43.9% was recorded 
among the patients.  It appears that the 
proportion of glandular dysplasia of the cervix 
in the study is probably higher than expected 
and the prediction of glandular cell carcinoma 
of the cervix may be on the increase in the 
future.  This is an area that will need further 
evaluation for clarification in the near future.
There is definitely a place for the use of LuViva 
advanced scan as a primary tool for cervical 
screening for dysplasia.  It is however important 
to exercise caution with the interpretation of the 
cytological classification.  Patients with high 
risk for cervical dysplasia may be recommended 
for further assessment with colposcopy and 
biopsywhile those with moderate and low risk 
can be repeated at six - twelve months and 3 
years interval respectively and final judgment 
made depending on the results and presentation.  
Further studies into the use of the LuViva 
advanced cervical scan in the primary screening 
for cervical dysplasia are recommended. 
Tables: 1 Age Distribution
Age (years)            Frequency      
<40                                                                             4
 
40-44                                                                    61
 
45-49                                                                    98 
50-54                         50
55-59                                                                    36 
>60
                                                                             
5
Total                                                                   254
 
 
Table 2:  Prior Pap Smear
YES                      1(0.39%) 
NO                       253(99.61%) 
TOTAL               254(100%) 
 
Table 3: Analysis Of Result Of Luviva Machine
Table 3a Parameter 1: Negative
LOW                             221(87.0%) 
MODERATE               16(6.3%) 
HIGH                            17(6.7%) 
TOTAL                         254(100%)                                                               
 
Table 3b Parameter 2:  Benign Changes
LOW                        186(73.5%)  
MODERATE           38(15.0%) 
HIGH                        29(11.5%)  
TOTAL                     253(100%)                                                               
88



















         AG
-U
S






























)    










    3
9(1
5.4
)       
3




)       
44(17.4)     






                 4
0(1
5.8
)       
4
1(16.2)       
42
(1
6.6)       
45(17.8)     























Figure 1: Categorization On Highest On Risk On 
Screenin Within The Age Group
Figure 2: Distribution Of Glandular Cells Dysplasia
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